Blocking leptin, STAT3 signaling, or fatty acid oxidation with the Cpt1 inhibitor etomoxir restored CD8+ TIL effector function and slowed tumor growth, with the latter finding reflecting the observations of Michelet et al. in their NK study. This evidence concerns the gene LEP and neoplasm.